-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
According to the information pending for the approval of the Food and Drug Administration, CSPC's mitoxantrone liposome has been approved for marketing
Mitoxantrone is a traditional broad-spectrum chemotherapy drug used for leukemia, lymphoma, etc.
The approved indication of CSPC's liposome formulation is for the treatment of relapsed or refractory peripheral T-cell lymphoma
Kunnoki's Akraki (eprisingsoft capsule) has passed the paper, and finally approves the listing, indications are very interesting :
It is used for unresectable hepatocellular carcinoma that is not suitable for or the patient refuses to receive standard treatment and has not received systemic systemic therapy before, and the patient's peripheral blood composite markers meet at least two of the following detection indicators: AFP≥400 ng/mL ; TNF-α<2.
(Is this a first-line drug?)